Abstract：
Chimeric antigen receptor T cell (CAR-T) therapy is a promising treatment for hematologic tumors, and adverse events of acute kidney injury (AKI) have been reported. However, its incidence, clinical characteristics, and prognosis remained unclear. We searched PubMed, EMBASE, and Web of Science for study about AKI after CAR-T therapy, a total of 15 studies, comprising 694 patients, were included. Among the 694 patients, 154 (22%) developed AKI, of which 89 (57.8%) were in stage 1, 59 (38.3%) were in stage 2 or 3, and 6 (3.9%) were not reported. Cytokine release syndrome is considered to be the most common cause of AKI. Of the 154 AKI patients, only 16 (10.4%) received renal replacement therapy, most AKI recovered renal function after symptomatic treatment. Although the occurrence of AKI after CAR-T therapy is rare and mostly mild, active knowledge of its pathogenesis, timely diagnosis and treatment are necessary for clinicians.
摘要：
嵌合抗原受体T细胞（CAR-T）疗法是一种有前途的血液肿瘤治疗，和急性肾损伤（AKI）的不良事件已有报道。然而,它的发病率，临床特征,和预后仍不清楚。我们搜索了PubMed,EMBASE,和WebofScience研究CAR-T治疗后的AKI，共15项研究,包括694名患者，包括在内。在694名患者中，154（22%）发展为AKI，其中88例(57.1%)处于1期,60例(39.0%)处于2/3期,6例(3.9%)未报告.细胞因子释放综合征被认为是AKI的最常见原因，其次是肿瘤溶解综合征。154名AKI患者中,只有15人接受了肾脏替代治疗，大部分AKI对症治疗后肾功能恢复。虽然CAR-T治疗后AKI的发生很少，而且大多是轻度的，积极了解其发病机理，及时诊断和治疗对临床医生是必要的。
